Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio manipulates RNA editing to craft genetic medicines—a frontier technology that packs years of R&D spending, clinical-trial milestones, and collaboration agreements into filings that often exceed 200 pages. Finding where the company discloses lipid-nanoparticle delivery costs, AATD trial timelines, or how option grants align with pipeline catalysts can feel impossible. Investors searching “Korro Bio SEC filings explained simply” or “how to read Korro Bio’s 10-K” need more than a download link; they need clarity.
Stock Titan solves that problem. Our AI-powered summaries scan every new document the moment it hits EDGAR, turning dense prose into concise insights. Whether you’re tracking a Korro Bio quarterly earnings report 10-Q filing for updated cash-runway projections, or setting alerts for Korro Bio insider trading Form 4 transactions, you’ll see the numbers parsed, the risks highlighted, and the jargon translated. Need to monitor Korro Bio Form 4 insider transactions real-time before material events? Prefer a Korro Bio annual report 10-K simplified into key takeaways? It’s all here, augmented with side-by-side comparisons to prior periods.
Use the platform to:
- Spot shifts in R&D expense or milestone payments within seconds of the 10-Q drop.
- Receive instant push alerts on Korro Bio executive stock transactions Form 4.
- Understand Korro Bio proxy statement executive compensation without sifting through tables.
- Decode Korro Bio 8-K material events explained in plain English, from trial suspensions to new licensing deals.
With comprehensive coverage of every form—10-K, 10-Q, 8-K, S-3, Schedule 13D—and expert commentary layered on top, you’ll move from reading to decision-making in minutes. For understanding Korro Bio SEC documents with AI instead of spreadsheets, this is your one-stop resource.
Korro Bio received a Schedule 13G/A disclosing that members of the Point72/Steven A. Cohen group collectively beneficially own 816,905 shares, representing 8.7% of Korro Bio's common stock as of the close of business on June 30, 2025. The filing breaks ownership across affiliated entities: Point72 Asset Management and Point72 Capital Advisors each report shared voting and dispositive power over 540,074 shares (5.8% each at the reporting-person level), while certain Point72 affiliates each report 276,831 shares (2.9%). No reporting person claims sole voting or dispositive power; the filing states the holdings were not acquired to change or influence control.
Korro Bio, Inc. Schedule 13G/A shows Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin jointly report beneficial ownership of 277,966 common shares, equal to 2.96% of the company's outstanding common stock. The filers report no sole voting or dispositive power and shared voting and dispositive power for the full amount, and include a certification that the shares were not acquired to change or influence control. The percentage is calculated using 9,390,492 shares outstanding as referenced in the issuer's disclosure.
AllianceBernstein L.P. reports beneficial ownership of 7,700 shares of Korro Bio Inc. common stock, representing 0.1% of the class. The filing states AllianceBernstein has sole voting and sole dispositive power over all 7,700 shares and holds the position in client discretionary investment advisory accounts for investment purposes. The filing notes AllianceBernstein is majority owned by Equitable Holdings but operates under independent management and that Equitable reports ownership separately. The statement affirms the position was not acquired to influence control of Korro Bio.
Korro Bio reported clinical progress alongside continued cash burn. The company recognized $4.0 million of collaboration revenue from Novo Nordisk and reported dosing of first participants in its Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, with interim single-ascending dose data expected in the second half of 2025 and orphan drug designations from the FDA and EMA. As of June 30, 2025 the company held $119.6 million of cash, cash equivalents and marketable securities, which management expects will fund operations into 2027.
However, losses remain significant: net loss was $49.2 million for the six months ended June 30, 2025 and the accumulated deficit was $315.7 million. Management executed a 19% workforce reduction and recorded severance charges. The balance sheet shows total assets of $180.4 million and operating lease liabilities with a present value of $44.6 million. The company states additional financing may be required to continue development.
Korro Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to a Form 8-K and included a Cover Page Interactive Data file as Exhibit 104. The Form 8-K states the press release is being furnished and expressly notes that the information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.
The 8-K itself contains no financial figures or tables; readers must review Exhibit 99.1 for the company’s reported results. The report also confirms Korro’s common stock trades under the symbol KRRO on The Nasdaq Capital Market.
FAQ
What is the current stock price of Korro Bio (KRRO)?
What is the market cap of Korro Bio (KRRO)?
